Vanadate oligomers: in vivo effects in hepatic vanadium accumulation and stress markers by Gândara, Ricardo M. C. et al.
JOURNAL OFwww.elsevier.com/locate/jinorgbio
Journal of Inorganic Biochemistry 99 (2005) 1238–1244
Inorganic
BiochemistryVanadate oligomers: In vivo eﬀects in hepatic
vanadium accumulation and stress markers
R.M.C. Gaˆndara a,*, S.S. Soares b, H. Martins a, C. Gutie´rrez-Merino c, M. Aureliano a
a CBME, Department Quı´mica e Bioquı´mica, FCT, Universidade do Algarve, Campus de Gambelas, 8005-139 Faro, Portugal
b CCmar, Department Ecologia e Recursos Vivos, FCMA, Universidade do Algarve, 8005-139 Faro, Portugal
c Depto. Bioquı´mica y Biologı´a Molecular, Facultad de Ciencias, Universidad de Extremadura, 06071 Badajoz, Spain
Received 13 January 2005; received in revised form 15 February 2005; accepted 23 February 2005
Available online 23 March 2005Abstract
The formation of vanadate oligomeric species is often disregarded in studies on vanadate eﬀects in biological systems, particularly
in vivo, even though they may interact with high aﬃnity with many proteins. We report the eﬀects in ﬁsh hepatic tissue of an acute
intravenous exposure (12, 24 h and 7 days) to two vanadium(V) solutions, metavanadate and decavanadate, containing diﬀerent
vanadate oligomers administered at sub-lethal concentration (5 mM; 1 mg/kg). Decavanadate solution promotes a 5-fold increase
(0.135 ± 0.053 lg V 1 dry tissues) in the vanadium content of the mitochondrial fraction 7 days after exposition, whereas no eﬀects
were observed after metavanadate solution administration. Reduced glutathione (GSH) levels did not change and the overall reac-
tive oxygen species (ROS) production was decreased by 30% 24 h after decavanadate administration, while for metavanadate, GSH
levels increased 35%, the overall ROS production was depressed by 40% and mitochondrial superoxide anion production decreased
45%. Decavanadate intoxication did not induce changes in the rate of lipid peroxidation till 12 h, but later increased 80%, which is
similar to the increase observed for metavanadate after 24 h. Decameric vanadate administration clearly induces diﬀerent eﬀects
than the other vanadate oligomeric species, pointing out the importance of taking into account the diﬀerent vanadate oligomers
in the evaluation of vanadium(V) eﬀects in biological systems.
 2005 Elsevier Inc. All rights reserved.
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Recent biological studies about vanadium reveals its
complex chemistry, being most of vanadium(V) biologi-
cal importance associated with the monomeric vanadate
ðHVO24 Þ, due to its structural similarity with phosphate
ðHPO24 Þ [1–3]. Besides monomeric vanadate species,
other vanadate oligomers can occur in vanadate solu-
tions, and such oligomers are known to promote diﬀer-
ent eﬀects in enzymes activities, not only in vitro [4,5]0162-0134/$ - see front matter  2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.jinorgbio.2005.02.023
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E-mail address: rmcgandara@gmail.com (R.M.C. Gaˆndara).but also in vivo [6,7]. Among vanadate oligomers, deca-
meric vanadate, which may occur upon medium acidiﬁ-
cation, was considered by Stankiewicz et al. [4] as the
vanadate oligomer with more biochemical relevance.
Although unstable at physiologic pH, the slow rate of
decameric vanadate decomposition allows studying its
eﬀects in biochemical systems [6–8].
Vanadium can induce the formation of reactive oxy-
gen species (ROS) in biological systems through: (i) Fen-
ton-like reactions [9]; (ii) vanadate bioreduction
mediated by reduced glutathione (GSH), ﬂavoenzymes
or NAD(P)H oxidases with ROS as a by-product [10–
15]; (iii) and recent evidences point out to an indirect
promotion of ROS production, probably by interacting
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ical eﬀects in several cell types have been related with
ROS production [16–19]. Nevertheless, vanadium was
recently reviewed as ‘‘an element of atypical biological
signiﬁcance’’ [20], due to insulin mimetic properties of
vanadium [16,21,22] and to the preventive eﬀects of
vanadium against animal carcinogens [23–26].
The role of vanadate oligomers in biological systems
is still to be clariﬁed and to our knowledge, in vivo tox-
icological studies of these species are almost inexistent.
In this sense, in the present study we have analyzed
the eﬀects of an intravenous administration of two dif-
ferent vanadate solutions, namely metavanadate and
decavanadate, on vanadium accumulation in liver and
on overall oxidative stress markers such as: (i) reduced
GSH content; (ii) overall rate of ROS production; (iii)
mitochondrial superoxide anion radical (O2 ) produc-
tion and (iv) lipid peroxidation propagation.Table 2
Reduced glutathione (GSH), reactive oxygen species (ROS), superox-
ide anion radical ðO2 Þ and lipid peroxides basal/control values in
hepatic tissue of Halobactrachus didactylus
Basal/control values
Reduced GSH content 7.8 ± 3.0 nmol mg1 protein
Overall ROS production 15.4 ± 6.1 a.u. min1 mg1 protein
Mitochondrial O2 production 6:4 nmol O2 min1 mg1 protein
Lipid peroxidation 46 ± 21 a.u. min1 mg1 protein
Values are presented as means ± SD (n = 3).2. Experimental
Specimens of Halobactrachus didactylus (toadﬁsh),
from both sexes, were caught in Ria Formosa lagoon
(in the south coast of Portugal), with body weight
339.8 ± 117.7 and 130.3 ± 28.6 g, and body length
26.9 ± 3.2 and 20.2 ± 1.3 cm, for vanadium accumula-
tion assays and for the overall oxidative stress studies,
respectively. They were acclimatized for no less than 2
weeks, and fed with squid ad libitum. The animals were
starved for 2 days before sacriﬁce. For vanadate accu-
mulation assays: 10 individuals were divided in two
groups (META and DECA groups) and treated with
an intravenous injection of 1 mg/kg of vanadium
(5 mM), as decavanadate and metavanadate, respec-
tively; sub-groups of ﬁve individuals were sacriﬁced 1
day and 7 days after injection, respectively. Simulta-
neously, at the beginning of the experiment, a control
group (n = 5) was sacriﬁced to determine basal values
(Table 1). For overall oxidative stress studies: six indi-
viduals were divided in two groups (META and DECA
groups) and treated with an intravenous injection of
1 mg/kg of vanadium (5 mM), as decavanadate and
metavanadate, respectively; sub-groups of three individ-
uals were sacriﬁced 12 and 24 h after injection, respec-Table 1
Vanadium amounts in total, mitochondrial and cytosolic fractions of hepati
CTRL META
Subcellular fractions 0 day 1 day
Total 0.434 ± 0.029 0.313 ± 0.180
Mitochondrial 0.023 ± 0.004 0.040 ± 0.008a
Cytosolic 0.022 ± 0.002 0.036 ± 0.014
CTRL, META and DECA refers to control, metavanadate (5 mM, 1 mg/kg)
time after administration in days. Values are presented as means ± SD (n =
a Signiﬁcantly diﬀerent from control, p < 0.05.tively. Simultaneously, at the beginning of the
experiment, a control group (n = 3) was sacriﬁced to
determine basal values (Table 2).
Metavanadate stock solution (50 mM, pH 6.7) was
prepared from ammonium metavanadate purchased
from Riedel-de-Haen. Decavanadate stock solution
was obtained by adjusting the pH of the former solution
to 4.0 [27]. Both metavanadate and decavanadate stock
solutions were always adjusted to pH 7.0 immediately
before using, diluted to the ﬁnal concentration (5 mM)
in physiological serum (NaCl 0.9%) and kept in ice be-
fore use. The concentrations of each vanadate species
were obtained by integrating the respective areas of
the NMR spectra and calculated by using an algorithm
described elsewhere [27]. NMR spectroscopy measure-
ments of vanadium were performed on a Bruker AM-
400 MHz spectrometer at 105.2 MHz equipped with a
5-mm multinuclear inverse probe. 51V NMR spectra of
5 mM metavanadate solution show that in addition to
about 692 lM monomeric (V1), also contains 210 lM
dimeric (V2), 830 lM tetrameric (V4) and lower
amounts of pentameric (V5) species, whereas 5 mM
decavanadate (equivalent to 500 M decameric species),
contain mainly the characteristic peaks of decameric
vanadate species (460 lM) and also monomeric
(400 lM) species, i.e., 1:1 decameric:monomeric species.
Whereas the metavanadate solution is stable, an esti-
mate half-life of 12 h was estimated for decameric spe-
cies that partially disintegrates in the injection medium
(0.9% NaCl), in agreement to described elsewhere for
1 mM total vanadium [7].
To obtain mitochondrial and cytosolic fractions, tis-
sues were removed, weighted and samples of 1 g were
homogenized with ultra-turrax at maximum speedc tissue from Halobatrachus didactylus
DECA
7 days 1 day 7 days
0.269 ± 0.240 0.646 ± 0.112 1.168 ± 0.523a
0.021 ± 0.011 0.051 ± 0.027 0.135 ± 0.053a
0.023 ± 0.020 0.057 ± 0.011 0.066 ± 0.042a
and decavanadate (5 mM, 1 mg/kg) group, respectively. 1 and 7 refer to
5) and given in lg V g1 dry tissue.
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10 ml of 20 mM tris(hydroxymethyl)aminometane (Tris)
(pH 7.6), 0.5 M sucrose, 0.15 M KCl, 1 mM ethylenedi-
aminetetraacetic acid dipotassium (EDTA), 1 mM dithi-
othreitol (DTT), and centrifuged at 460g for 10 min at
4 C. The supernatants were then centrifuged at
10,000g for 30 min at 4 C. The 10,000g supernatants
were centrifuged at 50,000g for 120 min at 4 C, and
the resulting supernatants (named as the cytosolic frac-
tion) were stored for vanadium accumulation assays.
The pellets were resuspended in 5 ml of the homogeniza-
tion buﬀer and again centrifuged at 10,000g for 30 min
at 4 C. The pellets containing the mitochondrial frac-
tion were resuspended in 3 ml of homogenization
solution and stored at 80 C for determination of
O2 production.
For vanadium concentration measurements, aliquots
of total, cytosolic and mitochondrial fractions were dried
at 80 C until constant weight and digested with 65% ni-
tric acid (HNO3) at the ratio of 20 ml per 1 g of dry
weight tissue. After the digestion, the residue was resus-
pended with 1 ml 10% chloridric acid (HCl). Vanadium
concentration were measured using a Varian AA20
atomic absorption spectrometer, equipped with a GTA-
96 graphite furnace, with auto sampler working at a fur-
nace program of 63 s with an argon gas ﬂow of 3.0 l/min.
The vanadium lamp was operated at 318.5 nm, with slit
width of 0.2 nm and the instrument was calibrated with
solutions containing 10, 20 and 40 ppb of vanadium. Cal-
ibration of the standards was obtained by successive dilu-
tions of a Merck standard solution of vanadium
1000 mg/l. TORT-1 was used as standard reference mate-
rial (1.4 ± 0.3 lg/g of vanadium).
Reduced GSH content was determined in fresh hepa-
tic tissue homogenates, from the reduction of 5,5 0-dithi-
obis (2-nitrobenzoic acid) (DTNB) by sulfhydryl groups
(e412 = 13.2 mM1 cm1). Brieﬂy, samples are supple-
mented with 20% of perchloric acid to precipitate pro-
teins. The mix was then centrifuged at 16,000g for
10 min at 4 C and the supernatant was neutralized with
KOH. These two steps were repeated twice. The assay
was performed in a medium containing 50 mM
KH2PO4, pH 7.0, 100 mM KCl and 0.5 mM DTNB.
The absorption value was registered after the addition
of sample with a Shimadzu UV mini1240.
The overall rate of ROS production in hepatic tissue
homogenates was calculated from the kinetics of in-
crease of ﬂuorescence (kexc = 495 nm, kem = 520 nm)
using dichlorodihydroﬂuorescein diacetate (H2DCFDA)
as probe [14,28]. Fluorescence measurements were car-
ried out under continuous stirring at 25 C with a Per-
kin–Elmer 650-40 Fluorescence Spectrophotometer
(Perkin–Elmer, Foster City, CA, USA). The assay
started after sample addition and was performed in a
medium containing 50 mM KH2PO4 (pH 7.0), 100 mM
KCl and 2 ng/ml H2DCFDA.Mitochondrial superoxide anion radical production
was measured from the rate of nitroblue tetrazolium
(NBT) reduction, as indicated elsewhere [29]. The assay
medium contains 50 mM KH2PO4 (pH 7.0), 100 mM
KCl, 0.1 mM EDTA, 0.1 mM NBT and 120 lg of pro-
tein of mitochondrial fraction of H. didactylus hepatic
tissue. Measurements were done at 560 nm with a Shi-
madzu UV mini1240. O2 production was calculated
from the decrease of the rate of NBT reduction after
addition of 350 U SOD.
Evaluation of lipid peroxidation propagation on he-
patic tissue homogenate was performed using cis-
parinaric acid (AcPn) [30]. Fluorescence measurements
(kexc = 332 nm, kem = 416 nm) were carried out under
continuous stirring at 25 C with a Perkin–Elmer
650-40 Fluorescence Spectrophotometer (Perkin–
Elmer, Foster City, CA, USA). The assay medium
contained 50 mM KH2PO4 (pH 7.0), 100 mM KCl,
12.5–25 ll of sample volume and 4 lM AcPn. Fluores-
cence readings started immediately after the addition
of AcPn.3. Results and discussion
Vanadium toxicity studies often disregard the forma-
tion of diﬀerent vanadate oligomers known to have dif-
ferent biochemical eﬀects and to interact with high
aﬃnity with many proteins such as, for example, myosin
[5]. Few animal studies involving vanadium consider the
contribution of diﬀerent oligomeric vanadate species to
vanadium toxicity. It has been recently shown that an
acute exposure to decavanadate but not to other vana-
date oligomers induced oxidative stress, lipid peroxida-
tion and a diﬀerent fate in vanadium intracellular
accumulation [6,7]. These ﬁndings were further explored
and the results described in the present article.
Our results demonstrated that there is a diﬀerent pat-
tern of vanadium accumulation when we compare meta-
vanadate and decavanadate solutions administration, in
total, mitochondrial and cytosolic fractions from H.
didactylus hepatic tissue (Table 1). The control value
for total vanadium accumulation in hepatic tissue, 0.43
(±0.03) lg/g dry tissue (Table 1), is within the range
of values reported for ﬁsh [31]. The basal vanadium con-
tent in hepatic tissue is 10 times higher than the value
reported for cardiac tissue [6]. The subcellular distribu-
tion of vanadium in liver appears to be diﬀerent than
in heart, since mitochondrial and cytosolic fractions of
hepatic tissue accumulate 10% of total vanadium, while
in cardiac tissue the same fractions accumulate 20% [6].
However, hepatic vanadium accumulation, with intrave-
nous administration, is diﬀerent than the accumulation
obtained in cardiac [6] and hepatic (data not shown) tis-
sue when an intraperitoneal administration was per-
formed. This ﬁnding is in agreement with the
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Fig. 1. Reduced glutathione content variation in the hepatic tissue of
Halobatrachus didactylus. META and DECA refers to metavanadate
(5 mM, 1 mg/kg) and decavanadate (5 mM, 1 mg/kg) groups, respec-
tively. Variation is calculated based on basal values (Table 1). 12 and
24 refers to time after administration in hours.
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on the way of administration [32].
It was observed that metavanadate solution adminis-
tration promoted weak increases in subcellular fractions
after 24 h but not in total vanadium content, and after 7
days no signiﬁcant diﬀerences between controls and
metavanadate intoxicated individuals were found (Table
1). On the contrary, there were increases in vanadium
concentration in all studied liver fractions after deca-
vanadate solution administration. After 24 h the total
vanadium content increased 50% (p < 0.005), while
mitochondrial fraction and cytosolic fraction increased
122% and 155% (p < 0.05), respectively. The increase
was much higher 7 days after exposition, particularly
in cytosolic and mitochondrial fraction which had 2-
and 5-fold increases (p < 0.05), respectively (Table 1).
Several reports have pointed out that mitochondria is
one of the target organelles for vanadium [33,34], and
our results of vanadium subcellular distribution showed
that the mitochondrial fraction tends to accumulate
more vanadium after decavanadate solution administra-
tion. This result suggests that decavanadate is not
behaving in the same way as other vanadate oligomers,
and indicate that decameric vanadate species will not
completely decompose into monomeric vanadate shortly
after administration.
Previous studies with erythrocytes have shown that
vanadate is transported inside through an unidentiﬁed
anionic channel [32,35] or that it is incorporated in
transferrin and albumin being rapidly transported to tis-
sues [36]. However, data were not found regarding to
decameric species. At pH 7, decameric vanadate might
not be present in solution depending on several param-
eters such as vanadium concentration, ionic strength or
temperature [8]. However, once formed at pH 4 and the
pH adjusted to physiological pH, it decomposes very
slowly with a half-time that can reach up to 15 h for
the ﬁrst order decomposition kinetics in serum [6,7].
This is an important feature, since decavanadate main-
tains its structure in serum for a signiﬁcant amount of
time. As decavanadate is eventually less permeant
through the anionic channel than the other vanadate
oligomers and likely to be bound with high aﬃnity to
proteins, therefore preventing its disintegration to vana-
date oligomers and reduction to vanadyl, we suggest
that the accumulation of vanadium in liver after deca-
vanadate administration is a consequence of a higher le-
vel of exposure of liver to total vanadium. It is known
that decavanadate binds with high aﬃnity with proteins
[4,5,8]. Moreover, it was demonstrated that, in certain
experimental conditions (but at physiological pH), the
half-life of 100 lM decameric vanadate species, as ascer-
tained by UV/vis, increases from 5 to 15 h, in the pres-
ence of the calcium pump from sarcoplasmic reticulum
(Aureliano and Gaˆndara, in press). At these decavana-
date concentrations and experimental conditions, UV/vis, is more sensitivite than NMR to follow the fate of
decavanadate in solution.
In hepatic tissue the GSH status is diﬀerently aﬀected
upon administration of the two diﬀerent vanadate solu-
tions. Whereas basal GSH content (7.8 ± 3.0 nmol
mg1 protein) did not show signiﬁcant changes after
decavanadate solution administration (Table 2, Fig. 1),
metavanadate solution administration increased GSH
status up to 20% and 35%, after 12 and 24 h, respectively
(Fig. 1). Since GSH was found to be involved in vana-
date bioreduction [10–15], the levels of GSH should be
aﬀected when vanadate is administered. Indeed, it has
been reported that the GSH pool is enhanced in the
presence of vanadate [23,39].
On the other hand, GSH is known to be one of the
most important intracellular anti-oxidants, being con-
sidered the largest component of an endogenous cellular
‘‘redox buﬀer’’ [37,38]. Therefore, diﬀerential eﬀects of
metavanadate and decavanadate on ROS production
should be expected on the light of the previous data.
Metavanadate-administered individuals showed a de-
crease of up to 40% in the overall rate of ROS produc-
tion (Fig. 2), which is consistent with the observed
increase in GSH content (Fig. 1). The decrease in ROS
was observed between 12 and 24 h (Fig. 2). On the con-
trary, decavanadate-administered groups have a weak
enhancement of ROS production 12 h after exposition
(approx. 15% increase), but after 24 h ROS production
decreased nearly 30%, mimicking the behavior observed
with metavanadate solution (Fig. 2). The simplest expla-
nation for this is that decomposition of decavanadate
will produce a delayed exposure of the liver to meta-
vanadate, although it is puzzling that no similar
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Fig. 2. Overall rate of ROS production variation in hepatic tissue of
Halobatrachus didactylus. META and DECA refers to metavanadate
(5 mM, 1 mg/kg) and decavanadate (5 mM, 1 mg/kg) groups, respec-
tively. Variation is calculated based on basal values (Table 1). 12 and
24 refers to time after administration in hours.
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Fig. 3. Superoxide anion radical ðO2 Þ production variation in the
mitochondrial fraction from Halobatrachus didactylus hepatic tissue.
META and DECA refers to metavanadate (5 mM, 1 mg/kg) and
decavanadate (5 mM, 1 mg/kg) groups, respectively. Variation is
calculated based on basal values (Table 1). 12 and 24 refers to time
after administration in hours.
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Fig. 4. Lipid peroxidation propagation variation in Halobatrachus
didactylus hepatic tissue. META and DECA refers to metavanadate
(5 mM, 1 mg/kg) and decavanadate (5 mM, 1 mg/kg) groups, respec-
tively. Variation is calculated based on basal values (Table 1). 12 and
24 refers to time after exposition in hours.
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described above (Fig. 1). Even though vanadium may
participate in Fenton-like reactions [9], together with
the proposed mechanisms of vanadate action that
involves its bioreduction and ROS production
[15,18,19,40], our results point out to a depression in
the overall rate of ROS production. This observation
is in good agreement with previous reports showing that
vanadate supplementation diminished oxidative stress in
certain experimental conditions, such as in rat-induced
hepatocarcinogenesis [23] and in rat diabetic tissues [41].
Regarding superoxide anion radical production in
mitochondrial fraction, once again it was observed that
metavanadate and decavanadate promoted opposite
eﬀects. Twelve hours after exposition, metavanadate-
administered individuals increased up to 45% in O2
production rate, while decavanadate administration
decreased 35% (Fig. 3). On other hand, after 24 h the
results are reverted, decavanadate promoted a 30% in-
crease, and metavanadate decreased O2 production in
40% (Fig. 3). Thus, decameric vanadate species induced
changes in O2 mitochondrial production opposite to
those produced by the oligomeric vanadate species that
are present in metavanadate solution, from which we
can suggest again diﬀerent pathways of biological action
for the diﬀerent oligomers. Several proposed vanadate
action pathways within cells involves O2 production
mediated by NADPH oxido-reductases from the respi-
ratory chain [15,18,19,40]. If we consider the action
and detoxiﬁcation mechanism proposed for vanadate,
where vanadate is reduced to vanadyl with production
of O2 , it is possible that decavanadate participates in
such reactions in a diﬀerent manner. Note also that after
24 h, the increase in O2 in decavanadate-administered
individuals correlated with the increase of vanadiumconcentration in the mitochondrial fraction (Table 2,
Fig. 3).
Lipid peroxidation is commonly observed following
enhanced ROS production in the cellular medium. In
metavanadate treated groups, it is observed an increase
of 55% and 80% in lipid peroxidation propagation after
12 and 24 h, respectively (Fig. 4). Decameric species do
not promote any signiﬁcant change 12 h after adminis-
tration, however, after 24 h the lipid peroxidation value
is similar to metavanadate-administered individuals
(Fig. 4). Without specifying which vanadate species were
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hepatic lipid peroxidation in induced hepatocarcinogen-
esis [23] and in 7,12-dimethylbenz(a)anthracene
(DMBA) induced mammary carcinogenesis [42] and
that vanadate does not change lipid peroxidation of con-
trol subjects [42]. We did not obtain any depression in
lipid peroxidation in hepatic tissue after vanadate
administration, even though there is maintenance of li-
pid peroxidation propagation until 12 h in decavana-
date-administered individuals. Twenty-four hours of
exposure to vanadate resulted in an increased rate of li-
pid peroxidation propagation, conﬁrming the results ob-
tain by our group with cardiac tissue [6]. Therefore,
decavanadate seems to have a delayed eﬀect in lipid per-
oxidation, probably due to its stability at physiological
pH. Earlier cellular responses induced by decameric
vanadate are currently being carried out looking for
shorten times of exposition such as 1, 2 and 6 h.4. Conclusions
Wehave shown that intravenous administrationof two
vanadate solutions, one of them containing decameric
vanadate, did result in diﬀerent vanadium accumulation
in H. didactylus hepatic tissue. The results support the
hypothesis of mitochondria as a target of decameric spe-
cies, since vanadium content in mitochondrial fraction
suﬀers a 5-fold increase and mitochondrial O2 produc-
tion was increased after decavanadate solution adminis-
tration. Additionally it is shown that vanadate
administration do not increase overall oxidative stress in
liver. Lipid peroxidation propagation rate was increased
by both vanadate solutions, suggesting that membrane
lipids should be also viewed as vanadate targets.
Several experimental observations on vanadate oligo-
merization state in relation with ROS production in he-
patic tissue were made in this work, however, more work
is needed to clarify whether vanadate speciation in vivo
could have diﬀerent roles and fates. Nevertheless, the re-
sults highlight that diﬀerent vanadate oligomers seem to
follow, not only in vitro but also in vivo, diﬀerent path-
ways, with diﬀerent targets and eﬀects. Although deca-
meric vanadate is not taken into consideration to
account for the eﬀect of vanadium in most biological
studies, it is to be noted that due to its unusual long sta-
bility at physiological pH, it may not completely decom-
pose into monomeric vanadate before inducing changes
in several cellular stress markers.
It is demonstrated that the administration of deca-
meric vanadate species, although partially disintegrates
in solution, induces diﬀerent eﬀects in liver oxidative
stress when compared with the administration of meta-
vanadate. This observation point out the importance
of taking into account decameric vanadate in the evalu-
ation of vanadium toxicity. It is believed that the presentstudy about the contribution of decavanadate to vana-
dium toxicity may be useful to gain a deeper knowledge
in vanadium biochemical eﬀects.Acknowledgments
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